Contraception in cancer survivors – an expert review Part II. Skin, gastrointestinal, haematological and endocrine cancers

References

• Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst. 1983;70:827–831.
   PubMedGoogle Scholar
• Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer. 1977;36:804–809.
   PubMed Web of Science ®Google Scholar
• Beral V, Evans S, Shaw H, et al. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer. 1984;50:681–685.
   PubMed Web of Science ®Google Scholar
• Rampen FH. Sex differences in survival from cutaneous melanoma. Int J Dermatol. 1984;23:444–452.
   PubMed Web of Science ®Google Scholar
• Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev. 1997;25:309–315.
   PubMedGoogle Scholar
• Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol. 1998;138:122–124.
   PubMed Web of Science ®Google Scholar
• Zanetti R, Franceschi S, Rosso S, et al. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol. 1990;19:552–561.
   Web of Science ®Google Scholar
• Smith M, Fine JA, Barnhill RL, et al. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol. 1998;27:751–757.
   PubMed Web of Science ®Google Scholar
• Global Cancer Observatory. 2018. All cancers. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf (accessed 15 March 2019).
   Google Scholar
• Da Silva FC, Wernhoff P, Dominguez-Barrera C, et al. Update on hereditary colorectal cancer. AR. 2016;36:4399–4405.
   Google Scholar
• Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–262.
   PubMed Web of Science ®Google Scholar
• Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21:9253–9261.
   PubMed Web of Science ®Google Scholar
• Cercek A, Siegel CL, Capanu M, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. Clin Colorectal Cancer. 2013;12:163–167.
   PubMed Web of Science ®Google Scholar
• Wan J, Gai Y, Li G, et al. Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer. Clin Colorectal Cancer. 2015;14:31–34.
   PubMed Web of Science ®Google Scholar
• Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631–650.
   PubMed Web of Science ®Google Scholar
• Lu KH, Loose DS, Yates MS, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus Depo-Provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013;6:774–781.
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36:124–129.
   PubMed Web of Science ®Google Scholar
• Maheshwari S, Sarraj A, Kramer J, et al. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506–513.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Chasle S, How CC. The effect of cytotoxic chemotherapy on female fertility. Eur J Oncol Nurs. 2003;7:91–98.
   PubMedGoogle Scholar
• Lo Presti A, Ruvolo G, Gancitano RA, et al. Ovarian function following radiation and chemotherapy for cancer. Eur J Obstet Gynecol Reprod Biol. 2004;113:S33–S40.
   PubMed Web of Science ®Google Scholar
• Falcone T, Attaran M, Bedaiwy MA, et al. Ovarian function preservation in the cancer patients. Fertil Steril. 2004;81:243–257.
   PubMed Web of Science ®Google Scholar
• Chen H, Xiao L, Li J, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2019;3:CD008018.
   PubMed Web of Science ®Google Scholar
• Elgindy E, Sibai H, Abdelghani A, et al. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126:187–195.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol. 2012;26:379–390.
   PubMed Web of Science ®Google Scholar
• Kane EV, Roman E, Becker N, et al. Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case–control studies. Ann Oncol. 2012;23:2362–2374.
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Lunghi F, Orlandi E, et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Hematologica. 2000;85:1032–1039.
   PubMed Web of Science ®Google Scholar
• Costas L, Lambert BH, Birmann BM, et al. A pooled analysis of reproductive factors, exogenous hormone use, and risk of multiple myeloma among women in the International Multiple Myeloma Consortium. Cancer Epidemiol Biomarkers Prev. 2016;25:217–221.
   PubMed Web of Science ®Google Scholar
• Roman E, Smith A, Appleton S, et al. Myeloid malignancies in the real-world: occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15. Cancer Epidemiol. 2016;42:186–198.
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27:4239–4246.
   PubMed Web of Science ®Google Scholar
• Spanish Association Against Cancer. Pancreatic cancer [in Spanish]. Available from: www.aecc.es/es/todo-sobre-cancer/tipos-cancer/cancer-pancreas (accessed 15 March 2019).
   Google Scholar
• Yaish I, Azem F, Gutfeld O, et al. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a prospective pilot study. Thyroid. 2018;28:522–527.
   PubMed Web of Science ®Google Scholar
• Evranos B, Faki S, Polat SB, et al. Effects of radioactive iodine therapy on ovarian reserve: a prospective pilot study. Thyroid. 2018. DOI:10.1089/thy.2018.0129
   PubMed Web of Science ®Google Scholar
• Braganza MZ, de González AB, Schonfeld SJ, et al. Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. Cancer Prev Res (Phila). 2014;7:418–425.
   PubMed Web of Science ®Google Scholar
• Xhaard C, Rubino C, Cléro E, et al. Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in young women in France: a population-based case-control study. Am J Epidemiol. 2014;180:1007–1017.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Survival rates for pancreatic cancer. Available from: www.cancer.org/cancer/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html (accessed 15 March 2019).
   Google Scholar
• Lee E, Horn-Ross PL, Rull RP, et al. Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. Am J Epidemiol. 2013;178:1403–1413.
   PubMed Web of Science ®Google Scholar
• Tang B, Lv J, Li Y, et al. Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore). 2015;94:e177.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Allolio B, Epidemiology of adrenocortical carcinoma. In: Hammer GD, Else T, eds. Adrenocortical carcinoma: basic science and clinical concepts. New York: Springer; 2010. p. 23–29.
   Google Scholar
• Patel A, Schwarz EB. Society of family planning. Cancer and contraception. Release date May 2012. SFP guideline #20121. Contraception. 2012;86:191–198.
   PubMed Web of Science ®Google Scholar
• Schwarz EB, Hess R, Trussell J. Contraception for cancer survivors. J Gen Intern Med. 2009;24:401–S406.
   PubMed Web of Science ®Google Scholar
• Rzepka J, Malmur M, Zalewski K, et al. Contraception for cancer survivors. Ginekol Pol. 2013;84:955–958.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. Geneva: WHO 2015.
   Google Scholar
• Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103.
   Web of Science ®Google Scholar
• Fassnacht M, Dekkers O, Else T, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1–G46.
   PubMed Web of Science ®Google Scholar
• Salenave S, Bernard V, Do Cao C, et al. Ovarian macrocysts and gonadotrope–ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. Eur J Endocrinol. 2015;172:141–149.
   PubMed Web of Science ®Google Scholar